Try our Advanced Search for more refined results
Life Sciences
-
October 27, 2025
Samsung Infringed Smart Ring IP, Suit Says
Smart ring maker Oura has hit Samsung with patent claims in Texas federal court, alleging the Korean electronics giant had been challenging Oura's patents in the U.S. before the launch of its allegedly infringing Samsung Galaxy Ring.
-
October 27, 2025
Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud
An investor in vaccine giant Moderna Inc. has failed to show that the company misrepresented the efficacy of its RSV vaccine by pointing out that the U.S. Food and Drug Administration later recalculated the vaccine's efficacy, the company said in an effort to slip a proposed investor class action.
-
October 27, 2025
Biotech Firm MapLight Inks $251M IPO Amid Shutdown
Biotechnology company MapLight Therapeutics began trading publicly Monday after raising $251 million in its initial public offering, which marked a rare listing during the ongoing federal government shutdown.
-
October 27, 2025
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court and Delaware Supreme Court saw another busy week of disputes spanning biotech milestones, reincorporation showdowns, shareholder voting schemes and cryptocurrency fiduciary rights.
-
October 27, 2025
Ex-Magellan CEO Avoids Prison Over Faulty Lead Tests
The former CEO of Magellan Diagnostics was sentenced in Massachusetts federal court Monday to a year of home confinement for failing to alert regulators to a problem in the company's lead-testing devices that resulted in inaccurately low lead levels being detected in blood samples.
-
October 27, 2025
Covington Helps Novartis Buy Avidity Biosciences For $12B
Swiss pharmaceutical giant Novartis AG has said it will buy Avidity Biosciences, a U.S. developer of therapeutics for muscle diseases, for approximately $12 billion in a move to boost its neuroscience portfolio.
-
October 24, 2025
Pfizer Hit With More Suits Over Depo-Provera
Three women sued Pfizer this week in Florida federal court, alleging its hormonal contraceptive birth control shot Depo-Provera caused their brain tumors in the latest claims that the major drugmaker failed to warn of the link.
-
October 24, 2025
Ohio, Ky. Reps Again Pursue Bill To Make PTAB Optional
A bipartisan pair of legislators in the U.S. House of Representatives are floating a bill that would give patent owners the ability to extinguish challenges to their intellectual property at the Patent Trial and Appeal Board before they start.
-
October 24, 2025
GNC Franchisee Cos. Largely Lose Bid To Toss Award Order
An international court judge has largely denied efforts by GNC franchisee businesses in Singapore and the Philippines to set aside an order enforcing arbitral awards totaling about $45 million that also enforced a contractual obligation to assign their 54 stores in Singapore to the health and wellness company.
-
October 24, 2025
USPTO Chief To Review PTAB Ruling On Tire Sensor Patent
U.S. Patent and Trademark Office Director John Squires has decided to step in and examine a Patent Trial and Appeal Board decision from September to consider a challenge to a Cerebrum Sensor Technologies Inc. tire sensor patent.
-
October 24, 2025
Tricida Investors Win OK Of $14.2M Deal Over Kidney Drug
A California federal judge on Thursday granted final approval to a $14.2 million settlement that ends a class action against Tricida Inc. founder Gerrit Klaerner claiming he and the company misled investors on the approval chances for their new kidney disease drug, including nearly $4 million for plaintiffs' counsel.
-
October 24, 2025
Generic-Drug Makers Want Conn. Price Cap Blocked During Suit
A trade group for generic and biosimilar drugmakers is asking a Connecticut federal judge to block the state's new drug price cap during the pendency of its challenge, saying it illegally controls prices on sales made outside the state.
-
October 24, 2025
Eli Lilly Buying Eye Disease Biotech For Up To $262M
Ropes & Gray LLP-advised Eli Lilly said Friday it has agreed to acquire Cooley LLP-guided Adverum Biotechnologies, a clinical-stage company developing gene therapies for eye diseases, for up to roughly $262 million.
-
October 24, 2025
Abbott Wins Third Bellwether In Cow Milk Baby Formula MDL
An Illinois federal judge has given Abbott Laboratories Inc. its third bellwether win in multidistrict litigation alleging that its cow-milk-based baby formula gives infants necrotizing enterocolitis, saying the company successfully demonstrated that the plaintiff's proffered human-milk-based alternative would not be feasible.
-
October 24, 2025
Taxation With Representation: Latham, Wachtell, Gibson Dunn
In this week's Taxation With Representation, Meta announces a joint venture with Blue Owl Capital to fund the development of a data center campus in Louisiana, private equity giants acquire medical technology company Hologic Inc., and National Fuel Gas Co. buys CenterPoint Energy Inc.'s Ohio natural gas utility business.
-
October 23, 2025
NY AG Sues Vape Shop Owners For Selling To Kids
New York's attorney general is looking to permanently shut down two smoke shops and ban their owners from ever working in the vape industry again, claiming they flagrantly sold illegal flavored vapes to customers including children, according to a petition filed Oct. 23.
-
October 23, 2025
Ky. Rep. Revives Attempt To Abolish PTAB, Expand Eligibility
U.S. Rep. Thomas Massie, R-Ky., said Thursday he's again attempting to overhaul the patent system, including abolishing the Patent Trial and Appeal Board, normalizing injunctions and broadening what can be patented.
-
October 23, 2025
Chancery Maps Out Math For Hefty Drug Co. Breach Interest
A Delaware vice chancellor late Thursday issued a road map for calculating tens of millions of dollars in interest due after a ruling in June that Alexion Pharmaceuticals failed a "best efforts" duty to fulfill an autoimmune drug candidate deal with Syntimmune Inc.
-
October 23, 2025
Investor Says Biotech Co. Rigged Votes To Expand Share Pool
A stockholder of Pennsylvania-based Ocugen Inc. sued the biotech company Thursday in Delaware Chancery Court, alleging that the company's board contrived a "clever" but unlawful scheme to push through a 2024 charter amendment that expanded its authorized share count without the required majority approval.
-
October 23, 2025
RingConn Settles With Oura After ITC Import Ban
Ouraring Inc. has inked a deal allowing RingConn to keep its smart rings on the U.S. market following the U.S. International Trade Commission's decision to block Ultrahuman and RingConn from importing products it held infringed a wearable computing device patent.
-
October 23, 2025
Freshly Launched Legal Org. Plans To Protect Abortion Docs
A new legal group launched this week aims to support telehealth doctors providing abortion pills and reproductive care, and to further strengthen shield laws protecting those providers from out-of-state prosecutions.
-
October 23, 2025
Bayer Wants Full Fed. Circ. Scrutiny Of Axed Xarelto Claims
Bayer Pharma Aktiengesellschaft is urging the full Federal Circuit to scrutinize a decision that declined to revive claims in a patent covering its blockbuster blood thinner, saying Wednesday that a panel wrongly concluded the term "clinically proven effective" couldn't count toward the claims' patentability.
-
October 23, 2025
SEC Being Misled In CBD Fraud Fight, CEO Claims
The U.S. Securities and Exchange Commission has "unwittingly" taken the side of a former partner with a terminated licensing agreement, a pharmaceutical CEO told a California federal court this week, asking for summary judgment on the SEC's core claims that he defrauded investors.
-
October 23, 2025
Ex-Exec Accused Of Stealing IVF Co.'s Trade Secrets
The co-founder of a Garden State genetic testing company abruptly quit, deleted all the data on his company laptop — including the only copy of some materials — then took the trade secrets to help a competitor, according to a lawsuit filed in New Jersey federal court.
-
October 23, 2025
Eli Lilly Says Pharmacy Mass-Producing Weight Loss Drug
Drugmaker Eli Lilly is suing a compounding pharmacy in Texas federal court, alleging the pharmacy ripped off its lucrative weight loss drug, began mass-producing it, and made as much as $2 million per month last year from its misdeeds.
Expert Analysis
-
DOJ-HHS Collab Crystallizes Focus On Health Enforcement
The recently announced partnership between the U.S. Department of Justice and U.S. Department of Health and Human Services to combat False Claims Act violations, following a multiyear trend of high-dollar DOJ recoveries, signals a long-term enforcement horizon with major implications for healthcare entities and whistleblowers, say attorneys at RJO.
-
Series
Law School's Missed Lessons: Learning From Failure
While law school often focuses on the importance of precision, correctness and perfection, mistakes are inevitable in real-world practice — but failure is not the opposite of progress, and real talent comes from the ability to recover, rethink and reshape, says Brooke Pauley at Tucker Ellis.
-
23andMe Fine Signals ICO's New GDPR Enforcement Focus
Many of the cybersecurity failures identified by the Information Commissioner’s Office in its investigation of 23andMe, recently resulting in a £2.3 million fine, were basic lapses, but the ICO's focus on several new U.K. General Data Protection Regulation considerations will likely carry into the future, say lawyers at Womble Bond.
-
Eye Drop Ruling Clarifies Importance Of Patent Phrasing
The Federal Circuit's recent ruling in Eye Therapies v. Slayback, rejecting the Patent Trial and Appeal Board's interpretation of "consisting essentially of," highlights the importance of using clear and consistent terms throughout a patent's filing history to shield it against future challenges, says Liliana Di Nola-Baron at Panitch Schwarze.
-
How The Healthline Privacy Settlement Redefines Ad Tech Use
The Healthline settlement is the first time California has drawn a clear line in the sand around how website tracking must function in practice, so if your site uses tracking technologies, especially around sensitive content like health or finance, regulators are inspecting your website's back end, not just its banner, say attorneys at Baker Donelson.
-
How Sweeping Budget Bill Shakes Up Health Industry
With the recently passed One Big Beautiful Bill Act marking one of the most significant overhauls of federal health policy since the passage of the Affordable Care Act, providers, managed care organizations and life sciences companies must now shift focus from policy review to implementation planning, say advisers at Holland & Knight.
-
Series
Adapting To Private Practice: From ATF Director To BigLaw
As a two-time boomerang partner, returning to BigLaw after stints as a U.S. attorney and the director of the Bureau of Alcohol, Tobacco, Firearms and Explosives, people ask me how I know when to move on, but there’s no single answer — just clearly set your priorities, says Steven Dettelbach at BakerHostetler.
-
A Look At Key 5th Circ. White Collar Rulings So Far This Year
In the first half of 2025, the Fifth Circuit has decided numerous cases of particular import to white collar practitioners, which collectively underscore the critical importance of meticulous recordbuilding, procedural compliance and strategic litigation choices at every stage of a case, says Joe Magliolo at Jackson Walker.
-
High Court Cert Spotlights Varying Tests For Federal Removal
A recent decision by the U.S. Supreme Court to review Chevron v. Plaquemines Parish, a case involving the federal officer removal statute, highlights three other recent circuit court decisions raising federal removal questions, and serves as a reminder that defendants are the masters of removal actions, says Varun Aery at Hollingsworth.
-
How To Increase 3rd-Party Preissuance Patent Submissions
Attorneys Marian Underweiser and Marc Ehrlich, who helped draft the America Invents Act, discuss changes that the U.S. Patent and Trademark Office could potentially implement to facilitate its hopes for increased participation in front-end patent challenges.
-
Trump Air Emissions Carveouts Cloud The Regulatory Picture
President Donald Trump's new proclamations temporarily exempting key U.S. industries from air toxics standards, issued under a narrow, rarely-used provision of the Clean Air Act, will likely lead to legal challenges and tighter standards in some states, contributing to further regulatory uncertainty, say attorneys at GableGotwals.
-
Series
Playing Baseball Makes Me A Better Lawyer
Playing baseball in college, and now Wiffle ball in a local league, has taught me that teamwork, mental endurance and emotional intelligence are not only important to success in the sport, but also to success as a trial attorney, says Kevan Dorsey at Swift Currie.
-
What US Medicine Onshoring Means For Indian Life Sciences
Despite the Trump administration's latest moves to onshore essential medicine manufacturing, India will likely remain an indispensable component of the U.S. drug supply chain, but Indian manufacturers should prepare for stricter compliance checks, says Jashaswi Ghosh at Holon Law Partners.
-
Series
Law School's Missed Lessons: Skillful Persuasion
In many ways, law school teaches us how to argue, but when the ultimate goal is to get your client what they want, being persuasive through preparation and humility is the more likely key to success, says Michael Friedland at Friedland Cianfrani.
-
FCA Working Group Reboot Signals EHR Compliance Risk
The revival of the False Claims Act working group is an aggressive expansion of enforcement efforts by the Justice Department and the U.S. Department of Health and Human Services targeted toward technology-enabled fraud involving electronic health records and other data, say attorneys at ArentFox Schiff.